Drug Profile
Research programme: therapeutic cancer vaccines - Abera Bioscience
Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Abera Bioscience AB
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Apr 2022 Abera Bioscience entered into partnership agreement with the Belgian neoantigen company myNEO for Personalised cancer vaccines
- 08 Apr 2021 Preclinical trials in Cancer in Sweden (unspecified route)
- 04 Jul 2016 Research programme: therapeutic cancer vaccines - Abera Bioscience is available for licensing-http://aberabio.com/partnering-licensing/